Patents by Inventor Philip A. Nunn

Philip A. Nunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile

Publication number: 20230124267

Abstract: Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed.

Type: Application

Filed: September 16, 2022

Publication date: April 20, 2023

Applicant: Principia Biopharma Inc.

Inventors: Steven Gourlay, Ann Neale, Philip Nunn, Claire Langrish, Olga Bandman, Dolca Thomas
TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

Publication number: 20210205312

Abstract: The present disclosure provides methods of treating a disease chosen from membranous nephropathy (MN), IgG4-related diseases, and antiphospholipid syndrome (APS) in a mammal using, e.g., a therapeutically effective amount of, the BTK inhibitor 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile or a pharmaceutically acceptable salt thereof.

Type: Application

Filed: January 5, 2021

Publication date: July 8, 2021

Inventors: Philip Nunn, Claire Langrish, Dolca Thomas
METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

Publication number: 20210106584

Abstract: Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed.

Type: Application

Filed: October 13, 2020

Publication date: April 15, 2021

Inventors: Steven GOURLAY, Ann NEALE, Philip NUNN, Claire LANGRISH, Olga BANDMAN, Dolca THOMAS
COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY

Publication number: 20180193274

Abstract: The current invention affords new formulations which deliver reversible and irreversible covalent kinase inhibitors, in particular BTK inhibitors, into the small intestine and specifically into the ileum and jejunum of the small intestine.

Type: Application

Filed: December 23, 2015

Publication date: July 12, 2018

Inventors: Philip A. NUNN, Bret BERNER, Mohammad Reza MASJEDIZADEH
SITE SPECIFIC DOSING OF A BTK INHIBITOR

Publication number: 20180015088

Abstract: Disclosed herein are formulations and methods of site specific administration of Compound (I) or a pharmaceutically acceptable salt thereof. Compound (I) is a potent BTK inhibitor and hence can be useful for the treatment of diseases such as cancer, autoimmune, and inflammatory diseases.

Type: Application

Filed: December 23, 2015

Publication date: January 18, 2018

Inventors: Philip NUNN, Bret BERNER, Mohammad Reza MASJEDIZADEH
Methods of treating genitourinary disorders using inhibitors of soluble epoxide hydrolase

Publication number: 20090082402

Abstract: The invention relates to methods of treating or preventing a disease state associated with a genitourinary disorder using inhibitors of soluble epoxide hydrolase.

Type: Application

Filed: December 18, 2007

Publication date: March 26, 2009

Inventors: Preston Albert Baecker, Thomas Chang, Alan H. Kosaka, Joseph S. Cefalu, Philip A. Nunn

Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile

TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-d]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY

SITE SPECIFIC DOSING OF A BTK INHIBITOR

Methods of treating genitourinary disorders using inhibitors of soluble epoxide hydrolase